Actively Recruiting
Phase 12 Study of Ivonescimab Infusion Treatment for Adults with Recurrent Glioblastoma
Led by M.D. Anderson Cancer Center · Updated on 2026-07-21
45
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying ivonescimab, a drug given by vein infusion, in adults with recurrent glioblastoma, a type of brain tumor that has returned after standard treatments. This clinical trial has two phases Phase 1 aims to find the highest dose of ivonescimab that patients can tolerate and recommend a dose for Phase 2. Phase 2 evaluates whether this recommended dose can help control the disease. The study is led by M.D. Anderson Cancer Center. Participants will receive ivonescimab through an intravenous infusion. The study includes two phases those who join early may enter Phase 1 to establish dosing, while others join Phase 2 to evaluate treatment effects at the recommended dose. Treatment and monitoring continue through these phases, with assessments to track safety and disease progression. During the trial, participants undergo regular evaluations including brain MRI scans, laboratory tests to check organ function, and monitoring for side effects. Safety and adverse events are closely tracked throughout the study, which lasts about one year on average. Researchers measure how well the drug is tolerated and its effects on disease progression, with ongoing follow-up until study completion.
CONDITIONS
Brief Title
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Research Team
E
Evguenia Gachimova, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
